Treating An Active Flare | SPEVIGO® (spesolimab-sbzo)

Complete pustular clearance within 1 week with SPEVIGO IV

People who experienced complete postular clearance at 1 week (%)

People who experienced complete postular clearance at 1 week. 54% (19 of 35 people) taking Spevigo and 6% (1 of 18 people) taking placebo.

Symptoms before Spevigo during an active flare.

Symptoms with Spevigo 1 week later.

This photo represents an individual from the SPEVIGO IV clinical trial, which measured how many people had no visible pustules 1 week after treatment, as well as safety, in people experiencing an active GPP flare.

Pustular clearance as early as DAY 2*

11% of people treated with SPEVIGO IV (4 out of 35) had no visible pustules vs no one (0 out of 18) taking placebo

These results are exploratory and were not the main purpose of the study, meaning they indicate a possible effect of SPEVIGO, and the results are less certain.

Individual results may vary based on many factors, including elements like the severity of your GPP, your treatment plan, and any other conditions you may have.

*These results are based on a clinical trial of 53 people with GPP.

“Placebo” means no active medication.

Measuring the impact on daily life

In addition, this study used 3 different tools to consider the impact of SPEVIGO on daily activities and emotions:

The pain visual analog scale (VAS).

The Pain Visual Analog Scale (VAS)

A rating scale that measures pain over time. Scores range from 0 (no pain) to 100 (severe pain).

The psoriasis symptom scale (PSS).

The Psoriasis Symptom Scale (PSS)

A 4-question scale used to assess the severity of pain, itching, redness, and burning during the past 24 hours. Questions are scored using a 5-point scale, ranging from 0 (none) to 4 (very severe). Total scores range from 0-16.

The functional assessment of chronic illness therapy-fatigue scale (FACIT-Fatigue).

The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue)

A 13-item scale that measures the impact of fatigue on daily activities. The impact on each item is scored using a 5-point scale, ranging from 0 (not at all) to 4 (very much). Total scores across all 13 activities range from 0-52, with lower scores indicating greater impact.

Across all 3 scales, people who received SPEVIGO IV reported:

Improved pain

Improved itching, redness, burning

Improved fatigue

Results were measured in 35 people 4 weeks after receiving SPEVIGO IV, compared to before treatment.

NOTE: In this study, all participants knew they were receiving SPEVIGO. This means that the study was not designed to confirm with certainty that SPEVIGO caused these results.

Starting a conversation with your doctor.

Take control of your GPP

This guide can help you prepare for a conversation with your doctor, including common questions to consider.

A doctor’s perspective on SPEVIGO

Listen to Dr Chovatiya explain the results when people received SPEVIGO in clinical trials.

Dr Chovatiya has been compensated for his participation.

GPP=generalized pustular psoriasis.
IV=intravenous.
SC=subcutaneous.

See how SPEVIGO SC helps control GPP after a flare

EXPLORE THE RESULTS

Indication

SPEVIGO is a prescription medicine used to treat generalized pustular psoriasis (GPP) in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg). It is not known if SPEVIGO is safe and effective in children under 12 years of age or who weigh less than 88 pounds (40 kg).

Please see the full Prescribing Information, including Medication Guide and Instructions for Use.

Important Safety Information
and Indication

Do not receive SPEVIGO if you or your child have had a severe or life-threatening allergic reaction to spesolimab-sbzo or any of the ingredients in SPEVIGO.

SPEVIGO may cause serious side effects, including:

Infections: SPEVIGO may lower the ability of your or your child’s immune system to fight infections and may increase your or your child’s risk of infections. Your healthcare provider should check you or your child for infections and tuberculosis (TB) before starting treatment with SPEVIGO and may treat you or your child for TB before you begin treatment with SPEVIGO if you have a history of TB or have active TB. Your healthcare provider should watch you or your child closely for signs and symptoms of TB during or after treatment with SPEVIGO. Tell your healthcare provider right away if you or your child have an infection or have symptoms of an infection during or after treatment with SPEVIGO, including, fevers, chills, or sweats, muscle aches, cough, shortness of breath, blood in your phlegm (mucus), burning when you urinate, urinating more often than normal
Allergic reactions and infusion-related reactions: Serious allergic reactions may happen during or after your or your child’s SPEVIGO injection. If you or your child have a serious allergic reaction, your healthcare provider will stop treatment with SPEVIGO. If you or your child are given SPEVIGO in a vein (intravenously) and have an infusion-related reaction, your healthcare provider will stop your or your child’s SPEVIGO infusion and treat your or your child’s symptoms and may restart SPEVIGO at a slower infusion rate. Tell your healthcare provider or get emergency medical help right away if you or your child get any of the following symptoms during or after your or your child’s SPEVIGO injection: feeling faint, dizzy, or lightheaded, swelling of your face, eyelids, lips, mouth, tongue, or throat, trouble breathing or throat tightness, fever, mouth sores, chest tightness, hives or skin rash that is different than the rash from generalized pustular psoriasis (GPP), itching, swollen lymph nodes

Before you or your child receive SPEVIGO, tell your healthcare provider about all of your medical conditions, including if you or your child:

have an infection that does not go away or that keeps coming back.
have TB or have been in close contact with someone with TB.
have recently received or are scheduled to receive an immunization (vaccine). You or your child should not receive live vaccines during and for at least 16 weeks after treatment with SPEVIGO. You or your child should be brought up to date with all vaccines before starting SPEVIGO.
are pregnant or plan to become pregnant. It is not known if SPEVIGO can harm your or your child’s unborn baby.
are breastfeeding or plan to breastfeed. It is not known if SPEVIGO passes into your breast milk. Talk to your healthcare provider about the best way to feed your or your child’s baby during treatment with SPEVIGO.

The most common side effects of SPEVIGO given in a vein (intravenously) for GPP flare treatment include feeling tired or weak, headache, nausea, itching or itchy bumps, a collection of blood under the skin at the infusion site or bruising, urinary tract infection

The most common side effects of SPEVIGO when given under the skin (subcutaneously) for treatment of GPP when not experiencing a flare include redness, pain, swelling, hardening, hives, or warmth at the injection site, joint pain, urinary tract infection, itching

These are not all of the possible side effects of SPEVIGO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information, including Medication Guide and Instructions for Use.

Read more Collapse